Compare Adaptive Biotechnologies Corp (ADPT) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Warner Music Group Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.01 (market cap $4.04B), while Warner Music Group Corp trades at $24.9 (market cap $13.12B). The key difference: Warner Music Group Corp is far larger — about 3.2× Adaptive Biotechnologies Corp's market cap, and Warner Music Group Corp pays a 3.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WMG | |
|---|---|---|
Market Cap | $4.04B | $13.12B |
Sector | Health | Media |
52-Week High | $25.45 | $34.72 |
52-Week Low | $12.30 | $23.65 |
Enterprise Value | $4.10B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Warner Music Group (WMG) trades at $24.62, down 6.78% in the past 24 hours, reflecting bearish technical momentum. The stock shows mixed fundamentals with recent earnings beats in Q1 and Q2 2026 but declining net income margins from 9.3% in 2022 to 5.44% in 2025. Strong institutional buying interest and a 66.66% analyst buy rating provide support despite near-term weakness.
WMG presents a compelling value opportunity with reasonable valuation multiples (P/E 20.06, P/S 1.8) and robust 9.2% projected 2026 net margin. Key risks include leadership transitions following the CFO's departure and streaming market competition, but strategic partnerships and price increases support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
